eli lilly glp-1 receptor agonist medications to seek approval of new weight-loss drug this year GLP-1 brands: Eli Lilly is
Description
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: A systematic review and meta-analysis of randomized controlled trials
More serious but rare adverse effects can include pancreatitis and gallbladder disease
2015;308:E6419
[DOI] [PubMed] [Google Scholar] 58.Kwon G., et al
